

State of Delaware Group Health Insurance

FY 2019, 2nd Quarter
Net Payments, Utilization and Trends from Incurred Claims



Notable Trends

For the current incurred rolling year period (January 1, 2018 – December 31, 2018) compared to the prior incurred rolling year period (January 1, 2017 – December 31, 2017) ¹:

- On a per member per month (PMPM) basis, net medical and drug payments increased from \$527 to \$550 (4.4%).
- Total net payments for medical and drug claims increased by 6.1% to \$712.7 million. The increase was driven by a \$21.5 million (10.4%) increase in drug payments that included a \$8.1 million (28.4%) increase in drug payments among high cost claimants (HCCs).
- A large portion of the 4.2% increase in the medical payments trend was attributable to outpatient facility claims (an increase of \$16.2 million and a 10.6% trend). Facility payments for outpatient surgery increased by \$6.5 million (10.3%) and facility payments for outpatient specialty drugs increased by \$4.8 million (22.2%).
- Payments for inpatient facility claims decreased by 5.3% from \$171 to \$162 per employee per month (PEPM) primarily driven by decreases in payments and utilization for facility inpatient surgery (declines of 16.3% and 12.9%, respectively).
- In terms of clinical conditions, the PMPM payments for chemotherapy encounters increased by 64.3% from \$6.85 to \$11.25 while obesity moved into the top 25 conditions with a 31.1% increase in PMPM from \$3.44 to \$4.55. Hypertension moved from 20th to 12th in rank among clinical conditions based on PMPM. The increase was largely attributable to a corresponding movement from 21st to 5th in rank among high cost claimants with a 90.8% trend in net payments.
- Utilization of urgent care facilities increased by 3.7% (from 465.7 visits per 1,000 to 482.8 visits per 1,000). Utilization of emergency rooms for services that could be provided in an urgent care setting decreased by 1.4 percent. PEPM payments for both urgent care visits and emergency visits increased (10.9% for urgent care visits and 2.4% for non-emergency visits to the ER).
- Utilization of high-tech radiology decreased at outpatient hospital facilities by 1.2 percent. However, payments increased from \$21 PEPM to \$23 (11.7%) PEPM at these facilities. High tech imaging utilization at freestanding facilities declined by 4.5%.
- Among the top five specialty drugs, payments for Trulicity (a diabetes medication) increased by 34.7% to \$4.9 million and payments for Stelara (an immunosuppressant used for inflammation) increased by 26.8% to \$2.8 million. Humira (an immunosuppressant used for inflammation) remains the top specialty drug with payments increasing by 4.3% to \$11.6 million.

¹Report covers Delaware payroll groups which include Merit Employees, Merit Retirees, Medicare Retirees, Public Education and Higher Education. Participating groups and the University of Delaware are excluded. Reported payment totals, PMPM and PEPM include a completion factor that estimates payments beyond the three months runout period for incurred claims.

Net Payments Summary & Top Clinical Conditions

Total Net Payments

	Jan 2017 - Dec 2017	Jan 2018 - Dec 2018	Trend
Total Medical and Rx	\$671,603,512	\$712,774,180	6.1%
Total Medical and Rx PMPM	\$527	\$550	4.4%

Medical and Rx Net Payments for Members and High Cost Claimants²


	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend	
	Net Pay Med	Net Pay Rx	Net Pay Med	Net Pay Rx	Net Pay Med	Net Pay Rx
All Members	\$463,648,652	\$207,932,076	\$483,249,422	\$229,495,694	4.2%	10.4%
HCCs	\$118,248,427	\$28,582,235	\$124,341,526	\$36,708,244	5.2%	28.4%
Members excluding HCCs	\$345,400,224	\$179,349,841	\$358,907,897	\$192,787,451	3.9%	7.5%



² High Cost Claimants (HCCs) are claimants with over \$100,000 total claims for the respective time periods.



Top Clinical Conditions by Net Payments



Rank Current	Rank Previous	MarketScan Rank	Clinical Condition	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			PMPM Trend
				Patients	Net Pay Med	PMPM	Patients	Net Pay Med	PMPM	
1	1	1	Prevent/Admin Hlth Encounters	66,618	\$23,012,357	\$18.25	69,527	\$25,367,891	\$19.63	7.5%
2	2	2	Signs/Symptoms/Oth Cond, NEC	33,342	\$19,825,803	\$15.72	35,038	\$21,263,366	\$16.45	4.6%
3	3	3	Osteoarthritis	11,440	\$16,480,524	\$13.07	11,572	\$16,583,349	\$12.83	-1.8%
4	4	4	Pregnancy without Delivery	2,019	\$15,310,448	\$12.14	1,983	\$15,979,209	\$12.36	1.8%
5	10	11	Chemotherapy Encounters	382	\$8,632,575	\$6.85	467	\$14,542,665	\$11.25	64.3%
6	7	5	Arthropathies/Joint Disord NEC	25,890	\$12,918,338	\$10.25	25,939	\$13,632,582	\$10.55	2.9%
7	6	6	Gastroint Disord, NEC	13,507	\$13,024,449	\$10.33	13,837	\$13,581,176	\$10.51	1.7%
8	5	7	Spinal/Back Disord, Low Back	13,439	\$14,306,028	\$11.35	13,673	\$12,707,410	\$9.83	-13.4%
9	8	9	Coronary Artery Disease	5,207	\$10,721,442	\$8.50	5,285	\$11,977,972	\$9.27	9.0%
10	9	10	Respiratory Disord, NEC	13,415	\$10,065,707	\$7.98	13,505	\$11,536,906	\$8.93	11.8%
11	14	18	Newborns, w/wo Complication	872	\$7,626,322	\$6.05	868	\$10,698,487	\$8.28	36.8%
12	20	35	Hypertension, Essential	23,162	\$6,171,463	\$4.89	23,814	\$8,256,027	\$6.39	30.5%
13	15	8	Renal Function Failure	3,040	\$7,314,889	\$5.80	3,140	\$7,838,936	\$6.06	4.5%
14	13	15	Spinal/Back Disord, Ex Low	9,605	\$7,697,891	\$6.11	9,693	\$7,601,288	\$5.88	-3.7%
15	18	21	Diabetes	14,433	\$6,737,295	\$5.34	14,550	\$7,245,088	\$5.61	4.9%
16	17	20	Cardiovasc Disord, NEC	9,513	\$6,752,164	\$5.36	9,709	\$6,806,451	\$5.27	-1.7%
17	11	13	Condition Rel to Tx - Med/Surg	2,649	\$8,525,079	\$6.76	2,596	\$6,630,685	\$5.13	-24.1%
18	16	22	Cerebrovascular Disease	3,694	\$6,945,175	\$5.51	3,796	\$6,452,666	\$4.99	-9.4%
19	12	14	Cardiac Arrhythmias	5,628	\$8,050,050	\$6.38	5,975	\$6,408,203	\$4.96	-22.3%
20	19	17	Cancer - Breast	1,401	\$6,651,029	\$5.28	1,434	\$6,317,190	\$4.89	-7.3%
21	22	16	Infections - ENT Ex Otitis Med	27,031	\$5,875,915	\$4.66	25,822	\$5,884,851	\$4.55	-2.3%
22	28	40	Overweight/Obesity	3,034	\$4,341,780	\$3.44	3,354	\$5,836,270	\$4.52	31.1%
23	23	24	Neurological Disorders, NEC	6,511	\$5,793,465	\$4.59	6,605	\$5,818,724	\$4.50	-2.0%
24	21	12	Infections, NEC	11,542	\$5,907,448	\$4.69	12,435	\$5,818,336	\$4.50	-3.9%
25	25	23	Infec/Inflam - Skin/Subcu Tiss	24,112	\$5,256,417	\$4.17	24,866	\$5,231,865	\$4.05	-2.9%



Net Pay Per Employee Per Month (PEPM) and Utilization Trends by Service Category for Last 12 Quarters















Service Category Net Pay Summary

Net Payments Trends for Service Category Groups

Service Category Group	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend PEPM
	Net Pay Med	Net Pay PEPM Med	Net Pay Med	Net Pay PEPM Med	
Facility Outpatient	\$133,762,593	\$183	\$150,010,351	\$203	10.6%
Facility Inpatient	\$124,719,620	\$171	\$119,739,779	\$162	-5.3%
Other Professional Services	\$65,326,952	\$89	\$70,030,221	\$95	5.7%
Physician Outpatient	\$65,940,216	\$90	\$67,031,919	\$91	0.3%
Radiology Outpatient	\$28,256,783	\$39	\$31,584,862	\$43	10.2%
Physician Inpatient	\$16,504,563	\$23	\$15,801,350	\$21	-5.6%
MHSA	\$16,976,193	\$23	\$15,571,273	\$21	-9.5%
Laboratory Outpatient	\$12,161,731	\$17	\$13,479,668	\$18	9.3%

Service Category Detail by Net Payments and Utilization

Facility Inpatient

Facility Inpatient Service Category	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Days per 1000	Net Pay Med	PEPM Med	Days per 1000	Net Pay Med	PEPM Med	Utilization	PEPM
Facility Inpatient Surgical	153.0	\$68,373,938	\$94	133.3	\$58,010,139	\$78	-12.9%	-16.3%
Facility Inpatient Medical	211.2	\$36,608,565	\$50	209.8	\$37,971,458	\$51	-0.7%	2.3%
Facility Inpatient Maternity	41.9	\$15,639,377	\$21	42.5	\$19,815,423	\$27	1.4%	25.0%
Facility Inpatient Long Term Care		\$4,023,482	\$6		\$3,859,457	\$5		-5.4%
Facility Inpatient Non Acute		\$74,258	\$0		\$83,302	\$0		10.6%

Facility Outpatient

Facility Outpatient Service Category	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Services per 1000	Net Pay Med	PEPM Med	Services per 1000	Net Pay Med	PEPM Med	Utilization	PEPM
Facility Outpatient Surgery	1,645.5	\$55,154,064	\$76	1,748.6	\$61,689,306	\$83	6.3%	10.3%
Facility Outpatient ER	2,292.0	\$36,176,542	\$50	2,360.6	\$38,707,359	\$52	3.0%	5.5%
Facility Outpatient Specialty Drugs	156.1	\$20,248,313	\$28	202.8	\$25,092,177	\$34	29.9%	22.2%
Facility Outpatient Diagnostic Services	210.9	\$7,269,830	\$10	213.2	\$8,027,594	\$11	1.1%	8.9%
Facility Outpatient Dialysis	310.4	\$5,067,121	\$7	293.1	\$5,411,255	\$7	-5.6%	5.3%
Facility Outpatient Other	489.7	\$3,558,115	\$5	519.7	\$4,450,782	\$6	6.1%	23.4%
Facility Outpatient Pharmacy	513.8	\$2,397,170	\$3	535.5	\$2,642,684	\$4	4.2%	8.7%
Facility Outpatient PT, OT, Speech Therapy	1,063.9	\$2,599,246	\$4	994.3	\$2,605,060	\$4	-6.5%	-1.2%
Facility Outpatient Home Health	42.2	\$528,958	\$1	49.8	\$562,648	\$1	17.9%	4.9%
Facility Outpatient Supplies and Devices	210.5	\$417,681	\$1	202.8	\$485,420	\$1	-3.7%	14.6%
Facility Outpatient Transportation	10.4	\$299,081	< \$1	10.1	\$285,512	< \$1	-3.6%	-5.8%
Facility Outpatient DME	1.8	\$46,472	< \$1	2.2	\$50,555	< \$1	21.0%	7.3%

Laboratory Services

Lab Services	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Services per 1000	Net Pay Med	PEPM Med	Services per 1000	Net Pay Med	PEPM Med	Utilization	PEPM
Laboratory Outpatient Other	2,289.63	\$4,137,213	\$5.67	2,352.50	\$4,774,743	\$6.45	2.7%	13.8%
Laboratory Outpatient Chemistry Tests	2,923.94	\$4,247,440	\$5.82	2,976.23	\$4,558,561	\$6.16	1.8%	5.9%
Laboratory Outpatient Pathology	553.69	\$3,777,078	\$5.17	594.01	\$4,146,365	\$5.60	7.3%	8.3%

Mental Health and Substance Abuse

MH / SA Services	Utilization Type	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Mental Health Other Outpatient	Visits per 1000	820.3	\$7,237,365	\$10	871.9	\$7,281,294	\$10	6.3%	-0.8%
Mental Health Inpatient	Days Per 1000	41.0	\$3,549,388	\$5	35.8	\$3,285,099	\$4	-12.6%	-8.7%
Substance Abuse Other Outpatient	Visits per 1000	60.2	\$2,635,008	\$4	81.9	\$1,816,988	\$2	36.2%	-32.0%
Mental Health Office Visits	Visits per 1000	289.4	\$1,635,216	\$2	298.7	\$1,636,903	\$2	3.2%	-1.3%
Substance Abuse Inpatient	Days Per 1000	20.2	\$1,840,310	\$3	17.0	\$1,458,424	\$2	-15.9%	-21.8%
Substance Abuse Office Visits	Visits per 1000	15.2	\$78,906	< \$1	17.5	\$92,563	< \$1	15.3%	15.7%

Non-Physician Professional Services

Non-Physician Professional Services	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Services / 1000	Net Pay Med	PEPM	Services / 1000	Net Pay Med	PEPM	Utilization	PEPM
Professional Specialty Drugs	270.2	\$19,040,141	\$26	271.7	\$21,049,117	\$28	0.6%	9.0%
Professional Services Other	584.3	\$10,990,313	\$15	635.7	\$10,854,214	\$15	8.8%	-2.6%
Professional PT, OT, Speech Therapy	4,321.3	\$7,154,149	\$10	4,730.6	\$7,858,575	\$11	9.5%	8.3%
Professional Diagnostic Services	1,438.9	\$6,152,098	\$8	1,484.8	\$6,747,085	\$9	3.2%	8.2%
Professional Office Visits	765.5	\$5,714,516	\$8	864.2	\$6,650,050	\$9	12.9%	14.8%
Professional Supplies and Devices	1,089.0	\$4,744,805	\$6	1,185.6	\$5,436,647	\$7	8.9%	13.0%
Professional DME	377.7	\$2,555,500	\$4	386.0	\$2,992,601	\$4	2.2%	15.5%
Professional Injections	761.9	\$2,793,491	\$4	717.1	\$2,542,440	\$3	-5.9%	-10.2%
Professional Chiropractic Services	817.3	\$2,089,061	\$3	839.6	\$2,240,048	\$3	2.7%	5.8%
Professional Transportation	193.2	\$2,697,440	\$4	180.0	\$2,194,828	\$3	-6.8%	-19.7%
Professional Home Health	150.5	\$1,192,191	\$2	148.0	\$1,248,514	\$2	-1.7%	3.3%
Professional Dialysis	27.4	\$203,246	< \$1	28.3	\$216,101	< \$1	3.5%	4.9%

Physician Inpatient Services

Physician Inpatient Services	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Services / 1000	Net Pay Med	PEPM	Services / 1000	Net Pay Med	PEPM	Utilization	PEPM
Physician Specialty Inpatient	940.4	\$11,951,590	\$16	872.8	\$11,221,249	\$15	-7%	-7%
Physician Non-Specialty Inpatient	597.6	\$4,552,973	\$6	618.7	\$4,580,101	\$6	4%	-1%

Physician Outpatient

Physician Outpatient Service Category	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Visits / 1000	Net Pay Med	PEPM	Visits / 1000	Net Pay Med	PEPM	Utilization	PEPM
Physician Non-Specialty Office Visits	2,737.8	\$20,840,045	\$29	2,697.1	\$21,379,689	\$29	-1%	1%
Physician Specialty Outpatient Surgery	415.5	\$17,979,736	\$25	397.2	\$17,774,610	\$24	-4%	-2%
Physician Specialty Office Visits	2,497.3	\$12,847,579	\$18	2,407.1	\$13,106,006	\$18	-4%	1%
Physician Specialty Outpatient Other	819.2	\$5,758,062	\$8	818.6	\$5,817,941	\$8	0%	0%
Physician Specialty ER	328.2	\$4,465,510	\$6	329.6	\$4,677,830	\$6	0%	3%
Physician Non-Specialty Outpatient Other	307.2	\$2,100,817	\$3	342.1	\$2,292,031	\$3	11%	8%
Physician Non-Specialty Outpatient Surgery	42.0	\$1,519,912	\$2	45.5	\$1,495,951	\$2	8%	-3%
Physician Non-Specialty ER	32.1	\$428,554	\$1	36.1	\$487,862	\$1	13%	12%

Radiology Services

Radiology Services	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Services/1000	Net Pay Med	PEPM	Services/1000	Net Pay Med	PEPM	Utilization	PEPM
Radiology Outpatient Therapeutic Radiology	218.1	\$8,004,526	\$11	221.9	\$8,840,523	\$12	1.7%	8.9%
Radiology Outpatient MRIs	161.0	\$4,647,183	\$6	154.1	\$4,995,783	\$7	-4.2%	6.0%
Radiology Outpatient Ultrasounds	414.8	\$4,331,563	\$6	409.2	\$4,854,400	\$7	-1.4%	10.5%
Radiology Outpatient CAT Scans	184.2	\$3,140,889	\$4	179.9	\$3,592,978	\$5	-2.3%	12.8%
Radiology Outpatient Mammograms	276.4	\$2,765,424	\$4	292.2	\$3,296,507	\$4	5.7%	17.6%
Radiology Outpatient X-Rays	781.8	\$2,223,971	\$3	758.0	\$2,671,737	\$4	-3.0%	18.5%
Radiology Outpatient Nuclear Medicine	75.3	\$1,747,035	\$2	71.9	\$1,863,497	\$3	-4.6%	5.2%
Radiology Outpatient Other	58.5	\$1,396,194	\$2	57.2	\$1,469,437	\$2	-2.2%	3.8%

Place of Service by Net Payments and Utilization

Laboratories

Place of Service - Lab	Utilization Type	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Outpatient Hospital-On Campus	Visits per 1000	610.1	\$10,775,561	\$15	614.3	\$10,902,831	\$15	0.7%	1.2%
Independent Laboratory	Visits per 1000	866.6	\$5,763,271	\$8	875.5	\$5,782,882	\$8	1.0%	0.3%
Ambulatory Surgical Center	Visits per 1000	8.8	\$148,820	< \$1	4.2	\$41,179	< \$1	-52.3%	-72.3%

Emergency Rooms & Urgent Care

Place of Service	Utilization Type	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Emergency Room (All Services)	Visits per 1000	382.3	\$47,347,068	\$65	387.3	\$49,666,944	\$67	1.3%	4.9%
Emergency Room (Urgent Care Services)	Visits per 1000	170.7	\$14,804,520	\$20	168.3	\$15,157,691	\$20	-1.4%	2.4%
Urgent Care Facility	Visits per 1000	465.7	\$4,610,517	\$6	482.8	\$5,112,098	\$7	3.7%	10.9%

Outpatient Hospital and Freestanding High-Tech Radiology

Place of Service	Utilization Type	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Outpatient Hospital	Visits per 1000	215.1	\$15,335,210	\$21	212.6	\$17,123,456	\$23	-1.2%	11.7%
Freestanding Facility	Visits per 1000	126.3	\$3,311,886	\$5	120.6	\$3,380,301	\$5	-4.5%	2.1%




Top 20 Physician Specialties by Net Payments and Utilization

Provider Type	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend	
	Services / 1000	Net Pay Med	PEPM	Services / 1000	Net Pay Med	PEPM	Utilization	PEPM
Pediatrician (NEC)	1,387.4	\$8,539,241	\$12	1,481.2	\$9,148,152	\$12	6.8%	5.7%
Family Practice	2,368.1	\$9,224,582	\$13	2,219.0	\$9,009,876	\$12	-6.3%	-3.7%
Orthopaedic Surgery	791.8	\$8,288,296	\$11	811.7	\$8,433,918	\$11	2.5%	0.4%
Obstetrics & Gynecology	670.8	\$8,542,630	\$12	634.9	\$8,192,433	\$11	-5.4%	-5.4%
Anesthesiology	342.6	\$8,140,182	\$11	312.2	\$8,012,109	\$11	-8.9%	-2.9%
Internal Medicine (NEC)	1,414.0	\$6,228,918	\$9	1,382.6	\$6,776,159	\$9	-2.2%	7.3%
Radiology	1,297.7	\$6,479,625	\$9	1,232.0	\$6,563,051	\$9	-5.1%	-0.1%
Emergency Medicine	382.9	\$4,831,526	\$7	372.7	\$4,945,517	\$7	-2.7%	1.0%
Cardiovascular Dis/Cardiology	1,031.9	\$4,766,123	\$7	1,030.8	\$4,856,262	\$7	-0.1%	0.5%
Ophthalmology	607.2	\$4,464,873	\$6	598.8	\$4,824,971	\$7	-1.4%	6.6%
Rheumatology	167.9	\$4,315,542	\$6	165.3	\$4,684,521	\$6	-1.6%	7.1%
Oncology	276.8	\$4,763,261	\$7	246.1	\$4,166,067	\$6	-11.1%	-13.7%
Gastroenterology	250.7	\$3,608,470	\$5	222.8	\$3,621,802	\$5	-11.1%	-1.0%
Chiropractor/DCM	1,358.0	\$2,973,585	\$4	1,444.1	\$3,240,193	\$4	6.3%	7.5%
Dermatology	573.8	\$2,675,409	\$4	568.7	\$2,809,138	\$4	-0.9%	3.6%
Surgeon (NEC)	238.9	\$2,945,540	\$4	196.1	\$2,543,104	\$3	-17.9%	-14.8%
Otolaryngology	284.5	\$2,736,324	\$4	274.9	\$2,449,435	\$3	-3.4%	-11.7%
Urology	304.2	\$1,997,112	\$3	316.5	\$2,123,216	\$3	4.0%	4.9%
Plastic/Maxillofacial Surgery	129.3	\$1,872,501	\$3	136.5	\$2,043,940	\$3	5.6%	7.7%
Neurology	186.4	\$2,047,328	\$3	170.9	\$2,019,328	\$3	-8.3%	-2.7%

Rx Net Pay, Utilization and Generic Efficiency

Mail/Retail by Days Supply, Generic Efficiency and Net Pay

	Jan 2017 - Dec 2017			Jan 2018 - Dec 2018			Trend		
	Days Supply Rx	Generic Efficiency	Net Pay PEPM Rx	Days Supply Rx	Generic Efficiency	Net Pay PEPM Rx	Days Supply Rx	Generic Efficiency	Net Pay PEPM Rx
Mail Order	9,877,345	90.2%	\$1,033	10,531,416	90.9%	\$1,217	6.6%	0.8%	17.8%
Retail	61,047,148	97.3%	\$2,425	61,051,711	96.4%	\$2,546	0.0%	-1.0%	5.0%
Total	70,924,493	96.8%	\$3,458	71,583,127	95.9%	\$3,763	0.9%	-0.9%	8.8%



Top 50 Non-Specialty Drugs

Product	Therapeutic Class	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
ELIQUIS	Blood Form/Coagul Agents	\$3,078,385.60	266,188	\$4,444,047.87	335,194	44.4%	25.9%
HUMALOG KWIKPEN	Hormones & Synthetic Subst	\$4,111,840.12	210,869	\$4,331,855.50	197,352	5.4%	-6.4%
JANUVIA	Hormones & Synthetic Subst	\$3,830,652.66	321,950	\$4,280,473.27	303,455	11.7%	-5.7%
XARELTO	Blood Form/Coagul Agents	\$2,910,932.71	250,973	\$3,778,692.70	282,701	29.8%	12.6%
LANTUS SOLOSTAR PEN	Hormones & Synthetic Subst	\$2,740,516.49	280,251	\$2,815,574.17	257,268	2.7%	-8.2%
VYVANSE	Central Nervous System	\$2,411,648.90	292,981	\$2,685,487.39	298,409	11.4%	1.9%
LYRICA	Central Nervous System	\$2,067,959.48	151,800	\$2,311,315.22	144,256	11.8%	-5.0%
HUMALOG	Hormones & Synthetic Subst	\$1,921,418.25	94,778	\$2,100,322.62	92,271	9.3%	-2.6%
CONCERTA	Central Nervous System	\$719,497.76	58,843	\$1,954,675.98	145,081	171.7%	146.6%
METFORMIN HCL	Hormones & Synthetic Subst	\$2,019,894.43	1,698,219	\$1,938,341.50	1,736,204	-4.0%	2.2%
JARDIANCE	Hormones & Synthetic Subst	\$962,708.73	73,092	\$1,913,823.52	127,419	98.8%	74.3%
INVOKANA	Hormones & Synthetic Subst	\$2,013,693.36	154,649	\$1,861,944.98	123,140	-7.5%	-20.4%
MYRBETRIQ	Smooth Muscle Relaxants	\$1,264,550.62	130,600	\$1,737,243.34	158,451	37.4%	21.3%
OXYCONTIN	Central Nervous System	\$1,637,823.89	79,791	\$1,563,844.93	68,210	-4.5%	-14.5%
SYMBICORT 160/4.5	Hormones & Synthetic Subst	\$1,376,150.07	156,319	\$1,524,367.87	157,083	10.8%	0.5%
ADDERALL XR	Central Nervous System	\$703,376.00	85,856	\$1,521,516.30	187,870	116.3%	118.8%
SPIRIVA	Autonomic Drugs	\$1,504,989.80	137,615	\$1,304,940.56	103,235	-13.3%	-25.0%
JANUMET	Hormones & Synthetic Subst	\$1,255,111.38	111,355	\$1,282,477.49	96,647	2.2%	-13.2%
LATUDA	Central Nervous System	\$941,631.33	24,546	\$1,270,846.26	29,636	35.0%	20.7%
ADVAIR DISKUS 250/50	Hormones & Synthetic Subst	\$1,260,180.20	117,443	\$1,214,543.51	97,650	-3.6%	-16.9%
TRESIBA	Hormones & Synthetic Subst	\$790,855.22	50,816	\$1,147,807.12	71,370	45.1%	40.4%
BREO ELLIPTA	Hormones & Synthetic Subst	\$767,640.65	81,180	\$1,119,781.70	108,105	45.9%	33.2%
LEVEMIR FLEXTOUCH	Hormones & Synthetic Subst	\$1,097,995.82	95,918	\$1,051,362.80	74,579	-4.2%	-22.2%
TOUJEO	Hormones & Synthetic Subst	\$974,673.98	71,781	\$1,022,844.62	66,351	4.9%	-7.6%
HUMALOG MIX 75/25 KP	Hormones & Synthetic Subst	\$1,017,496.34	39,705	\$1,022,388.01	34,815	0.5%	-12.3%
ONE TOUCH ULTRA	Diagnostic Agents	\$1,231,273.96	364,937	\$981,283.00	294,432	-20.3%	-19.3%


Product	Therapeutic Class	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
ANDROGEL	Hormones & Synthetic Subst	\$989,731.06	40,989	\$950,573.97	33,810	-4.0%	-17.5%
VESICARE	Smooth Muscle Relaxants	\$910,834.56	96,274	\$899,098.62	79,354	-1.3%	-17.6%
MESALAMINE	Gastrointestinal Drugs	\$443,898.64	21,780	\$873,174.45	45,505	96.7%	108.9%
XIFAXAN	Anti-Infective Agents	\$734,475.11	10,924	\$872,711.27	11,357	18.8%	4.0%
MOMETASONE FUROATE	Eye, Ear, Nose Throat	\$1,035,256.46	195,850	\$868,874.62	165,702	-16.1%	-15.4%
LO LOESTRIN FE	Hormones & Synthetic Subst	\$705,635.49	181,095	\$826,196.43	194,726	17.1%	7.5%
LIBRAX	Autonomic Drugs	\$487,323.61	4,778	\$794,930.70	5,170	63.1%	8.2%
EZETIMIBE-SIMVASTATIN	Cardiovascular Agents	\$519,358.87	133,192	\$774,703.15	204,861	49.2%	53.8%
METOPROLOL SUCCINATE	Cardiovascular Agents	\$617,646.18	1,154,077	\$746,113.21	1,270,148	20.8%	10.1%
ESOMEPRAZOLE MAGNESIUM	Gastrointestinal Drugs	\$1,101,869.24	830,418	\$735,538.61	781,694	-33.2%	-5.9%
RANEXA	Cardiovascular Agents	\$710,501.79	57,492	\$723,694.68	53,543	1.9%	-6.9%
BYSTOLIC	Cardiovascular Agents	\$630,529.01	181,479	\$716,169.65	184,754	13.6%	1.8%
PRADAXA	Blood Form/Coagul Agents	\$997,657.71	90,528	\$714,596.57	56,649	-28.4%	-37.4%
RESTASIS	Eye, Ear, Nose Throat	\$788,177.41	56,905	\$711,029.96	44,475	-9.8%	-21.8%
LINZESS	Gastrointestinal Drugs	\$575,274.44	51,623	\$701,460.69	57,035	21.9%	10.5%
VASCEPA	Cardiovascular Agents	\$400,237.19	60,642	\$617,725.03	81,337	54.3%	34.1%
PROAIR HFA	Autonomic Drugs	\$517,114.34	365,515	\$592,562.57	375,099	14.6%	2.6%
JANUMET XR	Hormones & Synthetic Subst	\$522,459.18	48,041	\$592,360.91	48,515	13.4%	1.0%
EZETIMIBE	Cardiovascular Agents	\$1,709,414.89	303,802	\$587,500.50	347,616	-65.6%	14.4%
ANORO ELLIPTA	Autonomic Drugs	\$357,306.35	33,953	\$584,807.33	46,482	63.7%	36.9%
FARXIGA	Hormones & Synthetic Subst	\$460,504.87	34,085	\$581,275.67	38,688	26.2%	13.5%
DEXILANT	Gastrointestinal Drugs	\$503,128.06	69,196	\$575,366.22	68,568	14.4%	-0.9%
MULTAQ	Cardiovascular Agents	\$609,429.19	35,827	\$573,272.16	29,760	-5.9%	-16.9%
BRILINTA	Blood Form/Coagul Agents	\$989,731.06	40,989	\$950,573.97	33,810	-4.0%	-17.5%

Top 50 Specialty Drugs


Product	Therapeutic Class	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
HUMIRA	Immunosuppressants	\$9,713,862.60	55,563	\$11,635,614.38	57,965	19.8%	4.3%
REVLIMID	Misc Therapeutic Agents	\$3,953,311.53	8,393	\$5,284,570.39	9,821	33.7%	17.0%
TRULICITY	Hormones & Synthetic Subst	\$3,197,661.17	146,859	\$4,952,530.25	197,784	54.9%	34.7%
ENBREL	Immunosuppressants	\$4,004,640.94	25,454	\$4,241,363.36	24,758	5.9%	-2.7%
STELARA	Immunosuppressants	\$2,119,865.88	8,971	\$2,805,748.80	11,378	32.4%	26.8%
GILENYA	Misc Therapeutic Agents	\$2,710,154.00	11,436	\$2,404,151.82	9,276	-11.3%	-18.9%
VICTOZA	Hormones & Synthetic Subst	\$2,055,344.83	88,176	\$2,222,338.25	77,483	8.1%	-12.1%
IBRANCE	Antineoplastic Agents	\$1,940,058.06	4,634	\$2,167,040.09	5,236	11.7%	13.0%
TECFIDERA	Misc Therapeutic Agents	\$1,451,316.38	6,432	\$1,732,778.06	7,064	19.4%	9.8%
SPRYCEL	Antineoplastic Agents	\$1,074,121.62	2,730	\$1,538,567.07	3,540	43.2%	29.7%
COSENTYX	Immunosuppressants	\$1,017,383.15	5,271	\$1,536,618.63	7,566	51.0%	43.5%
OTEZLA	Misc Therapeutic Agents	\$983,513.74	10,168	\$1,507,403.84	14,160	53.3%	39.3%
IMBRUVICA	Antineoplastic Agents	\$1,233,738.11	3,300	\$1,444,753.88	3,218	17.1%	-2.5%
XTANDI	Antineoplastic Agents	\$861,212.66	2,484	\$1,356,455.99	3,784	57.5%	52.3%
HARVONI	Anti-Infective Agents	\$1,856,121.60	1,652	\$1,338,364.37	1,176	-27.9%	-28.8%
FORTEO	Misc Therapeutic Agents	\$1,196,677.61	11,570	\$1,279,175.64	10,505	6.9%	-9.2%
XELJANZ XR	Immunosuppressants	\$639,840.74	5,010	\$1,275,910.45	9,180	99.4%	83.2%
COPAXONE	Misc Therapeutic Agents	\$1,540,096.89	8,356	\$1,193,346.22	6,762	-22.5%	-19.1%
GENVOYA	Anti-Infective Agents	\$861,377.41	9,210	\$1,139,042.44	11,220	32.2%	21.8%
CABOMETYX	Antineoplastic Agents	\$185,372.66	316	\$992,184.16	1,404	435.2%	344.3%
TASIGNA	Antineoplastic Agents	\$842,874.84	2,100	\$985,441.78	2,167	16.9%	3.2%
POMALYST	Antineoplastic Agents	\$716,006.07	1,393	\$947,624.08	1,057	32.3%	-24.1%
XELJANZ	Immunosuppressants	\$958,404.29	7,484	\$841,394.98	6,210	-12.2%	-17.0%
IMATINIB MESYLATE	Antineoplastic Agents	\$582,527.54	2,130	\$786,532.84	3,390	35.0%	59.2%
REPATHA	Cardiovascular Agents	\$477,234.01	10,946	\$786,319.26	18,374	64.8%	67.9%
OFEV	Antineoplastic Agents	\$644,283.02	2,190	\$755,695.87	2,340	17.3%	6.8%

Product	Therapeutic Class	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
PROMACTA	Blood Form/Coagul Agents	\$494,858.71	1,350	\$714,988.74	1,324	44.5%	-1.9%
AUBAGIO	Immunosuppressants	\$526,873.51	2,464	\$686,516.70	2,940	30.3%	19.3%
ZYTIGA	Antineoplastic Agents	\$959,686.05	3,050	\$658,689.33	1,970	-31.4%	-35.4%
ALECENSA	Antineoplastic Agents	\$150,481.26	348	\$635,008.83	1,460	322.0%	319.5%
ESBRIET	Respiratory Tract Agents	\$510,601.66	1,860	\$623,373.65	2,070	22.1%	11.3%
OPSUMIT	Cardiovascular Agents	\$461,913.28	1,650	\$607,315.09	1,950	31.5%	18.2%
LETAIRIS	Cardiovascular Agents	\$592,907.15	1,950	\$602,652.47	1,920	1.6%	-1.5%
AVONEX PEN	Misc Therapeutic Agents	\$555,189.24	2,442	\$601,974.20	2,352	8.4%	-3.7%
AFINITOR	Antineoplastic Agents	\$440,478.69	786	\$600,962.04	1,132	36.4%	44.0%
JAKAFI	Antineoplastic Agents	\$730,002.73	1,890	\$596,314.20	1,644	-18.3%	-13.0%
TRUVADA	Anti-Infective Agents	\$435,715.71	8,235	\$591,927.32	10,396	35.9%	26.2%
TRIUMEQ	Anti-Infective Agents	\$463,990.86	5,250	\$568,287.92	5,910	22.5%	12.6%
XOLAIR	Immunosuppressants	\$533,544.94	4,956	\$567,432.32	5,376	6.4%	8.5%
VOTRIENT	Antineoplastic Agents	\$321,784.65	942	\$559,536.56	1,510	73.9%	60.3%
ADEMPAS	Cardiovascular Agents	\$385,702.38	1,244	\$529,799.06	1,587	37.4%	27.6%
PRALUENT	Cardiovascular Agents	\$285,634.55	6,872	\$528,786.02	13,992	85.1%	103.6%
AMPYRA	Central Nervous System	\$581,237.39	8,010	\$519,782.01	6,240	-10.6%	-22.1%
NORDITROPIN FLEXPRO	Hormones & Synthetic Subst	\$476,325.53	3,478	\$511,526.48	3,668	7.4%	5.5%
ACTEMRA	Immunosuppressants	\$262,433.14	2,464	\$510,370.48	3,965	94.5%	60.9%
TALTZ	Immunosuppressants	\$181,322.95	868	\$496,094.00	2,016	173.6%	132.3%
PRIVIGEN	Serums, Toxoids, Vaccines	\$70,806.16	168	\$481,678.01	840	580.3%	400.0%
DUPIXENT	Immunosuppressants	\$122,161.25	1,039	\$480,829.38	4,284	293.6%	312.3%
GAMUNEX-C	Serums, Toxoids, Vaccines	\$386,882.47	1,461	\$476,835.26	1,649	23.3%	12.9%
BEXAROTENE	Antineoplastic Agents	\$292,250.19	405	\$425,201.96	615	45.5%	51.9%

Top 5 Non-Specialty Products – 12 Month Trends



Top 5 Specialty Products – 12 Month Trends



High Cost Claimants (HCCs)

Service Category Group Net Pay and Utilization for HCCs

Service Category Group	Utilization Type	Jan 2017 - Dec 2017		Jan 2018 - Dec 2018		Trend	
		Utilization	Net Pay Med	Utilization	Net Pay Med	Utilization	Net Pay
Facility Inpatient	Patients	490	55,369,715	471	52,346,820	-3.9%	-5.5%
Facility Outpatient	Patients	705	34,385,130	763	42,231,399	8.2%	22.8%
Other Professional Services	Patients	760	9,743,715	817	11,419,261	7.5%	17.2%
Radiology Outpatient	Patients	661	7,119,683	724	7,875,934	9.5%	10.6%
Physician Inpatient	Patients	516	5,311,955	495	4,854,188	-4.1%	-8.6%
Physician Outpatient	Patients	770	2,550,930	837	2,681,505	8.7%	5.1%
MHSA	Patients	208	2,709,798	223	1,758,330	7.2%	-35.1%
Laboratory Outpatient	Patients	717	1,057,501	774	1,174,090	7.9%	11.0%

Top Clinical Conditions Among High Cost Claimants

Rank	Rank	Clinical Condition	Jan 2017 – Dec 2017		Jan 2018 – Dec 2018		Net Pay Trend
Current	Previous		Patients	Net Pay Med	Patients	Net Pay Med	
1	1	Chemotherapy Encounters	122	\$7,426,538	144	\$12,828,005	72.7%
2	4	Coronary Artery Disease	123	\$3,953,753	145	\$5,218,835	32.0%
3	3	Renal Function Failure	153	\$4,364,113	160	\$4,949,984	13.4%
4	10	Newborns, w/wo Complication	17	\$3,026,393	23	\$4,202,127	38.8%
5	21	Hypertension, Essential	321	\$2,109,790	355	\$4,026,470	90.8%
6	6	Spinal/Back Disord, Low Back	170	\$3,724,580	171	\$3,435,517	-7.8%
7	17	Multiple Sclerosis	38	\$2,431,861	40	\$3,418,652	40.6%
8	14	Cancer - Lung	49	\$2,830,537	66	\$3,337,802	17.9%
9	22	Gastroint Disord, NEC	292	\$2,093,835	274	\$3,230,216	54.3%
10	8	Radiation Therapy Encounters	55	\$3,169,089	55	\$3,117,111	-1.6%
11	5	Cardiac Arrhythmias	172	\$3,731,206	187	\$2,949,046	-21.0%
12	2	Condition Rel to Tx - Med/Surg	194	\$4,912,154	166	\$2,804,228	-42.9%
13	13	Infections, NEC	137	\$2,936,189	163	\$2,770,614	-5.6%
14	9	Cancer - Breast	62	\$3,164,823	64	\$2,732,697	-13.7%
15	16	Signs/Symptoms/Oth Cond, NEC	610	\$2,558,383	647	\$2,589,525	1.2%
16	24	Respiratory Disord, NEC	390	\$1,980,555	405	\$2,525,920	27.5%
17	15	Cerebrovascular Disease	93	\$2,758,339	101	\$2,389,620	-13.4%
18	20	Tumors - Central Nervous Sys	29	\$2,173,529	39	\$2,195,232	1.0%
19	30	Cancer - Lymphoma	24	\$1,346,647	28	\$2,143,461	59.2%
20	19	Neurological Disorders, NEC	190	\$2,205,741	223	\$1,895,021	-14.1%
21	11	Musculosk Disord, Congenital	19	\$3,006,038	27	\$1,662,265	-44.7%
22	18	Cancer - Nonspecified	109	\$2,320,564	115	\$1,600,700	-31.0%
23	12	Cardiovasc Disord, Congenital	20	\$3,002,138	22	\$1,562,775	-47.9%
24	26	Cardiovasc Disord, NEC	265	\$1,863,151	300	\$1,537,434	-17.5%
25	25	Mental Hlth - Substance Abuse	48	\$1,920,680	49	\$1,447,472	-24.6%

High Cost Claimants – Top Therapeutic Classes

Therapeutic Class	Jan 2017 – Dec 2017		Jan 2018 – Dec 2018		Trend	
	Net Pay Rx	Patients	Net Pay Rx	Patients	Net Pay	Utilization
Antineoplastic Agents	\$10,859,528	164	\$14,544,651	183	33.9%	11.6%
Misc Therapeutic Agents	\$5,128,189	184	\$6,896,944	182	34.5%	-1.1%
Immunosuppressants	\$3,030,428	69	\$4,347,210	72	43.5%	4.3%
Cardiovascular Agents	\$1,928,434	521	\$2,302,072	553	19.4%	6.1%
Anti-Infective Agents	\$1,396,297	574	\$1,303,507	599	-6.6%	4.4%

Glossary

Days per 1000 Adm Acute - the average number of days from acute admissions per 1000 members with medical coverage per year.

Days Supply – is the number of days for which drugs were supplied for prescriptions filled.

Generic Efficiency – the number of prescriptions filled with a generic drug, expressed as a percentage of all prescriptions filled that could have been filled with a generic drug.

Svcs Per 1000 – the average number of services provided under medical coverage per 1000 members with medical coverage per year.

Visits per 1000 – the average number of outpatient facility visits under medical coverage, per 1000 members with medical coverage per year.